Apollo Therapeutics
Biologics developed via academic-collaboration model
Privately held: no public share price · United Kingdom
Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | ZIP12 (zinc transporter)Monoclonal antibody | Pulmonary Arterial Hypertension | |
| Phase 2 | IL-18Monoclonal antibody | Atopic Dermatitis | |
| Phase 2 | GLP-1 receptor; FGF21 receptorProtein / enzyme therapeutic | ObesityType 2 Diabetes | |
| Phase 1 | GCN2 (EIF2AK4)Small molecule | Acute Myeloid Leukemia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
August 2027 (1)
October 2027 (1)
camoteskimabPhase 2Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Est. primary completion 2027-10-31 · NCT07599813 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
16 September 2025Topline resultcamoteskimabPhase 2a CHAMELEON (NCT06436183) of camoteskimab in atopic dermatitis met its primary endpoint (EASI at week 16)
Financial reports
No financial reports recorded.